HomeCompareSGHDY vs ABBV

SGHDY vs ABBV: Dividend Comparison 2026

SGHDY yields 1.72% · ABBV yields 3.09%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SGHDY wins by $33.53M in total portfolio value· pulled ahead in Year 4
10 years
SGHDY
SGHDY
● Live price
1.72%
Share price
$10.20
Annual div
$0.17
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$33.64M
Annual income
$30,249,562.53
Full SGHDY calculator →
ABBV
AbbVie Inc.
● Live price
3.09%
Share price
$214.96
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$103.7K
Annual income
$25,324.79
Full ABBV calculator →

Portfolio growth — SGHDY vs ABBV

📍 SGHDY pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSGHDYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SGHDY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SGHDY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SGHDY
Annual income on $10K today (after 15% tax)
$145.78/yr
After 10yr DRIP, annual income (after tax)
$25,712,128.15/yr
ABBV
Annual income on $10K today (after 15% tax)
$262.96/yr
After 10yr DRIP, annual income (after tax)
$21,526.07/yr
At 15% tax rate, SGHDY beats the other by $25,690,602.08/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SGHDY + ABBV for your $10,000?

SGHDY: 50%ABBV: 50%
100% ABBV50/50100% SGHDY
Portfolio after 10yr
$16.87M
Annual income
$15,137,443.65/yr
Blended yield
89.73%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SGHDY
No analyst data
Altman Z
2.8
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+19.2% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SGHDY buys
0
ABBV buys
0
No recent congressional trades found for SGHDY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSGHDYABBV
Forward yield1.72%3.09%
Annual dividend / share$0.17$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$33.64M$103.7K
Annual income after 10y$30,249,562.53$25,324.79
Total dividends collected$33.35M$62.2K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SGHDY vs ABBV ($10,000, DRIP)

YearSGHDY PortfolioSGHDY Income/yrABBV PortfolioABBV Income/yrGap
1$11,043$343.00$11,555$434.96$512.00ABBV
2$12,524$707.99$13,485$635.47$961.00ABBV
3$14,902$1,500.82$15,933$937.67$1.0KABBV
4← crossover$19,282$3,337.82$19,118$1,400.80+$164.00SGHDY
5$28,705$8,073.11$23,384$2,125.24+$5.3KSGHDY
6$53,179$22,464.02$29,290$3,286.81+$23.9KSGHDY
7$134,689$77,787.37$37,776$5,205.38+$96.9KSGHDY
8$512,372$368,254.79$50,495$8,488.44+$461.9KSGHDY
9$3,166,715$2,618,477.70$70,497$14,346.44+$3.10MSGHDY
10$33,637,948$30,249,562.53$103,718$25,324.79+$33.53MSGHDY

SGHDY vs ABBV: Complete Analysis 2026

SGHDYStock

SG Holdings Co.,Ltd., through its subsidiaries, engages in the delivery, logistics, and real estate businesses in Japan and internationally. It offers domestic or international delivery services; logistics solutions, including warehouse storage, needle and product inspection, and logistics processing to sea, air, and land transport; and international transport, customs clearance, and regional transport and delivery services. The company also operates, manages, and leases real estate facilities; and engages in renewable energy business. In addition, it develops, operates, and maintains in IT systems; operates temporary staffing business; and operates casualty insurance agency for transport operations and truck fuel sales. The company was founded in 1957 and is headquartered in Kyoto, Japan.

Full SGHDY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SGHDY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SGHDY vs SCHDSGHDY vs JEPISGHDY vs OSGHDY vs KOSGHDY vs MAINSGHDY vs JNJSGHDY vs MRKSGHDY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.